You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Rapid Clinical Surge-Testing for Biothreat Agents

    SBC: FIRST LIGHT BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Following a bioterrorist attack, hundreds of thousands of potential victims may require testing and treatment. The critical need to test large numbers of people for exposure to a biothreat agent may overwhelm the capacity of the clinical and public health infrastructure. The approximately 25,000 sentinel laboratories in the Laboratory Response Network, which co ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an anti-malaria toxin vaccine candidate

    SBC: ANCORA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Malarial disease represents one of the most pressing medical healthcare issues facing the world today. While limited drug treatment options exist, a vaccine solution is widely considered as one of the most effective therapeutic weapons to combat malaria. Despite years of research, though, malarial vaccine initiatives have yet to produce a viable candidate. One ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  3. High Field Magnets for MRI Applications

    SBC: Supercon, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The specific aim of the Phase I and Phase II research program will be to design and build an "open", split pair coil, high field (>1 .5T), cryogen-free MRI magnet. The key innovation that will make this goal feasible is the development of an advanced, high performance, round high temperature superconductor capable of operation at 20 Kelvin. Operating at a te ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  4. Spectral imaging for automated malignant blast counting

    SBC: CAMBRIDGE RESEARCH AND INSTRUMENTATION            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to extend our successful development of an agile spectral light source for light microscopy, funded through the NCI-IMAT initiative, into FDA trials. The SpectraLamp(tm) device enables the automated and quantitative analysis of double-immunostained samples in brightfield (non-fluorescence-based) microscopy, with particular utility for hematopatho ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Hyperspectral Assessment & Prediction of Diabetic Foot U

    SBC: Hypermed, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Foot disease complications seriously impact lives of people with Type 1 diabetes. A quantitative method to evaluate efficacy of therapy, or better, to define tissue at risk & prevent initial ulcer formation would be highly beneficial. HYPERMED'S long-term objective is to reduce frequency of foot ulcers & amputation by developing Foot HyperSpectral Imaging (FHSI ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Hyperspectral Assessment & Prediction of Diabetic Foot U

    SBC: Hypermed, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Foot disease complications seriously impact lives of people with Type 1 diabetes. A quantitative method to evaluate efficacy of therapy, or better, to define tissue at risk & prevent initial ulcer formation would be highly beneficial. HYPERMED'S long-term objective is to reduce frequency of foot ulcers & amputation by developing Foot HyperSpectral Imaging (FHSI ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  7. A nitric oxide synthase inhibitor for uveitis

    SBC: Inotek Pharmaceuticals Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Steroid treatment of anterior uveitus is effective but frequently associated with cataract formation after prolonged use. Development of an effective substitute for steroids, free of these safety concerns, would be a substantial advance. In a Phase I SBIR, we proposed a novel therapeutic candidate for treatment of uveitus, based on the introduction of a proprie ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. DNA Polymerase IIIe, A New Antibiotic Target

    SBC: GLSynthesis Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): In phase I we have identified a new class of active-site directed inhibitors of DMA polymerase HIE, a novel replicative enzyme in Gram+ bacteria. The compounds, 7-substituted-N2-(3,4-dichlorobenzyl)guanines "DCBGs", are potent enzyme inhibitors, and selected derivatives have potent and broad activity against clinically relevant Gram+ bacteria. We have identifi ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Immunoaffinity Isolation of Phosphopeptides

    SBC: CELL SIGNALING TECHNOLOGY, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Among post-translational modifications, protein phosphorylation is particularly relevant to cancer biology and therapy. However, despite advances in proteomics, it is still difficult to pinpoint phosphorylation sites in proteins. The long-term goal of this project is to develop and commercialize a multiplexed method for isolating, identifying, and quantifying ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic for the Negative Symptoms of Schizophrenia

    SBC: Darpharma, Inc.            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Schizophrenia affects roughly 1% of the world's population, with more than two million Americans afflicted in any given year, and an estimated 30-50 million people worldwide. Treatment with available antipsychotic medications often effectively attenuates the positive symptoms of schizophrenia without improvement in the negative symptoms or cognitive deficits. F ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government